CD274 and non-small cell lung carcinoma: Pembrolizumab is approved as a first-line therapy for NSCLC with elevated PD-L1 expression, and in combination with platinum and pemetrexed for nonsquamous NSCLC, regardless of PD-L1 expression levels [2,8,9,10].